Catalyst Pharmaceuticals Inc CPRX R2KPHARMA
Company Overview
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Why Investors Should Care
Generates a return on equity of 24.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 26.9%.
Net profit has compounded at 23.4% per year over the last five years.
Revenue has grown at a 37.7% CAGR over the past five years.
Trades at a P/E of 18.2, below the sector median of 25.2.
Maintains a net profit margin of 37.1%.
Recent Developments
- Dec 2025 Revenue of $588.99M (+19.8% YoY); net profit $214.33M.
- Trailing 12 Months Year-on-year growth — revenue +5.6%, earnings +11.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 37.7%, profit CAGR 23.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 37.68% |
| 1 Year: | 5.60% |
Compounded Profit Growth
| 5 Years: | 23.37% |
| 1 Year: | 11.10% |
Stock Price Performance
| 1 Year: | +0.00% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
P/E of 18.20 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 24.5%.
- Healthy ROCE of 26.9%.
- Excellent profit margin of 37.1%.
- Compounding revenue at 37.7% over 5 years.
- Profit CAGR of 23.4% over 5 years.
- Generates positive free cash flow.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CPRX Catalyst Pharmaceuticals Inc R2KPHARMA | 31.49 | 18.20 | $3.85B | 0.00% | 26.94% | 24.50% | 37.68% | 23.37% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.45M | 28.84M | 30.90M | 30.12M | 29.14M | 29.61M | 29.32M | 30.20M | 36.37M | 35.95M | 43.09M | 53.11M | 57.24M | 85.37M | 99.58M | 102.69M | 98.51M | 122.71M | 128.69M | 141.42M | 146.56M | 148.39M | 149.39M |
| Operating Income | -3.98M | -4.29M | -4.90M | -5.02M | -6.19M | -6.24M | -4.81M | -3.91M | -4.31M | -4.68M | -4.18M | -4.31M | -5.51M | -5.93M | -6.34M | -8.18M | -14.84M | -987.77K | 10.96M | 13.85M | 8.01M | 10.70M | 10.28M | 11.70M | 9.80M | 15.84M | 14.00M | 17.37M | 28.57M | 25.10M | 35.61M | 46.70M | -37.19M | 27.13M | 54.25M | 50.91M | 63.37M | 66.30M | 66.27M | 73.23M |
| Net Income | -3.49M | -5.41M | -4.56M | -4.45M | -5.82M | -5.39M | -4.57M | -3.95M | -4.16M | -4.97M | -3.88M | -4.18M | -5.39M | -5.70M | -5.97M | -7.84M | -14.50M | -644.50K | 10.96M | 13.63M | 7.93M | 10.43M | 9.78M | 43.34M | 7.66M | 12.18M | 10.33M | 13.24M | 21.62M | 22.75M | 29.57M | 37.76M | -30.76M | 23.27M | 40.79M | 43.88M | 56.74M | 52.11M | 52.78M | 63.73M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.06 | -0.08 | - | -0.01 | 0.10 | 0.13 | 0.07 | 0.10 | 0.09 | 0.41 | 0.07 | 0.11 | 0.10 | 0.12 | 0.20 | 0.20 | 0.26 | 0.33 | -0.29 | 0.19 | 0.33 | 0.35 | 0.45 | 0.41 | 0.42 | 0.50 |
| R&D Expense | - | 2.35M | 2.58M | 3.04M | - | 3.55M | 2.51M | 2.49M | - | 2.81M | 2.45M | 2.70M | - | 3.26M | 3.70M | 4.54M | - | 3.31M | 4.63M | 4.60M | - | 4.22M | 4.35M | 3.75M | 3.01M | 4.45M | 4.49M | 3.40M | 3.98M | 8.31M | 3.56M | 3.95M | 83.66M | 2.58M | 2.98M | 3.28M | 3.89M | 4.36M | 2.66M | 2.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 500.00K | 102.31M | 119.07M | 140.83M | 214.20M | 398.20M | 491.73M | 588.99M |
| Operating Income | - | - | - | - | - | - | - | -7.28M | -4.02M | -6.08M | -5.22M | -10.31M | -14.59M | -20.40M | -19.28M | -18.68M | -35.30M | 31.82M | 41.30M | 52.38M | 101.84M | 86.81M | 195.12M | 257.78M |
| Net Income | -255.94K | -428.62K | -539.82K | -1.81M | -2.73M | -4.14M | -10.56M | -7.24M | -4.01M | -6.39M | -4.08M | -12.15M | -15.51M | -20.23M | -18.07M | -18.41M | -34.00M | 31.88M | 74.98M | 39.48M | 83.08M | 71.41M | 163.89M | 214.33M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.33 | 0.30 | 0.71 | 0.37 | 0.75 | 0.63 | 1.31 | 1.68 |
| R&D Expense | - | - | - | - | - | - | - | 5.10M | 2.31M | 3.38M | 2.66M | 8.10M | 10.12M | 11.80M | 11.37M | 11.38M | 19.92M | 18.84M | 16.50M | 16.94M | 19.79M | 93.15M | 12.65M | 12.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2002 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | 5.83M | 6.25M | 16.79M | 25.37M | 43.91M | 60.10M | 41.71M | 85.39M | 60.45M | 112.38M | 192.35M | 237.79M | 375.63M | 470.11M | 851.41M | 1.10B |
| Total Equity | 100.00K | 44.89K | 362.56K | 117.58K | 446.46K | 19.85M | 16.32M | 10.56M | 7.62M | 5.52M | 3.76M | 14.62M | 21.39M | 35.24M | 55.48M | 39.31M | 80.96M | 50.78M | 87.63M | 169.60M | 206.83M | 300.42M | 387.88M | 727.63M | 954.27M |
| Cash & Equivalents | 100.00K | - | - | - | - | - | - | 11.77M | 7.78M | 5.48M | 6.03M | 1.41M | 2.22M | 9.10M | 28.24M | 13.89M | 57.50M | 16.56M | 89.51M | 130.24M | 171.44M | 298.39M | 137.64M | 517.55M | 709.17M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | 313.71K | 2.49M | 2.17M | 3.98M | 8.67M | 4.63M | 2.40M | 4.42M | 9.67M | 24.75M | 22.76M | 30.96M | 75.21M | 82.23M | 123.78M | 149.71M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | 298.96K | 833.80K | 1.65M | 2.14M | 5.86M | 3.44M | 2.09M | 4.27M | 9.51M | 24.10M | 22.76M | 27.06M | 57.59M | 76.06M | 120.68M | 147.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.68M | -3.76M | -4.99M | -5.14M | -9.88M | - | - | - | -13.74M | -26.15M | 34.61M | 45.03M | 60.37M | 116.05M | 143.60M | 239.81M | 208.67M |
| Investing Cash Flow | -2.30K | -2.87K | -3.62K | -14.06M | -7.50M | - | - | - | -3.96K | -15.08M | 37.23M | -5.01M | -11.02M | 9.21M | -293.50M | -556.00K | -58.00K |
| Financing Cash Flow | 3.70M | 1.46M | 5.54M | 14.58M | 18.18M | - | - | - | 57.35M | 293.12K | 1.12M | 702.00K | -8.14M | 1.69M | -10.86M | 140.66M | -16.99M |
| Capital Expenditure | -2.30K | -2.87K | -3.62K | -52.38K | -9.43K | -57.32K | -23.46K | -96.06K | - | -92.02K | -19.00K | -11.00K | -1.02M | -29.00K | -231.00K | -556.00K | -58.00K |
| Free Cash Flow | -7.69M | -3.76M | -4.99M | -5.19M | -9.89M | - | - | - | - | -26.24M | 34.59M | 45.02M | 59.35M | 116.02M | 143.37M | 239.25M | 208.61M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 12.09M | 6.91M | 0 | 0 | 25.30M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7,059.0% | 31.1% | 34.7% | 37.2% | 47.5% | 21.8% | 39.7% | 43.8% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6,800.7% | 31.2% | 63.0% | 28.0% | 38.8% | 17.9% | 33.3% | 36.4% |
| ROE % | -570.2% | -118.2% | -459.1% | -404.4% | -13.8% | -25.4% | -100.0% | -95.1% | -72.6% | -169.9% | -27.9% | -56.8% | -44.0% | -36.5% | -46.0% | -22.7% | -67.0% | 36.4% | 44.2% | 19.1% | 27.7% | 18.4% | 22.5% | 22.5% |
| ROCE % | - | - | - | - | - | - | - | - | -72.7% | -112.3% | -34.5% | -44.4% | -38.3% | -36.0% | -48.7% | -23.0% | -69.3% | 36.0% | 24.4% | 24.9% | 32.0% | 22.0% | 26.7% | 26.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.34% | 18.77M | $591.21M |
| 2 | State Street Corporation | 5.61% | 6.86M | $216.12M |
| 3 | Vanguard Capital Management LLC | 4.18% | 5.12M | $161.31M |
| 4 | American Century Companies Inc | 3.38% | 4.14M | $130.32M |
| 5 | Deerfield Management Company, L.P | 3.22% | 3.94M | $124.18M |
| 6 | Dimensional Fund Advisors LP | 2.80% | 3.43M | $108.00M |
| 7 | Bank of America Corporation | 2.48% | 3.04M | $95.62M |
| 8 | Geode Capital Management, LLC | 2.43% | 2.97M | $93.60M |
| 9 | Morgan Stanley | 2.20% | 2.69M | $84.62M |
| 10 | Vanguard Portfolio Management LLC | 2.02% | 2.48M | $77.95M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CPRX
Nasdaq moves to delist Catalyst Pharmaceuticals (Nasdaq: CPRX) common stock - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOZllzOUc5cnBma3ZLZ3RwZWpXWFlpNDRENVdvR3ZsenRmSTRPYVFSeXBWdzg1Y3JHLWctWXNtWlhtZkFzOFNSUU5pSXVGNDAtaTZPZEhwR1p5bThIYUozWGtUMjFSTFFpQTFVck1wOUtUVEo5bjRzUFVuN190T2loYXZJbHNTNEI0UGZObk…
CPRX or UTHR: Which Is the Better Value Stock Right Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQYXhyWU5qODFwQW9MUWRuOHZTSi10ZFRvYnFQSFdpbGlvV2ZsaDVwbURDdUJ0bmk4eTl5SzM2U3pLMF9sOFp5Q2VlRWlCOFdmOGJvWHdIWmdzR0lheDA0WnNmYzJhLXhsU2RLOXFpZXlPTUozSzJnTFRKNm9udmM3SEJmeU1KaGhuWU1GUX…
CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
<a href="https://news.google.com/rss/articles/CBMinAJBVV95cUxPNXhsQ2tWVGlrRGZ4cnlmekdkQVRVc3owZGs0ZHRNR0paUHV2Z3BQN252cE9yZFdVU0owd1BTWWZNT0pRbTBiYlpBY3lrVWxMUDcwbDVIUDBtR0NMa1hOWkZSZGZGUjZ3dW1vczdMOFZVOGhqQ2ZENHF4aElHODctY0JfR29ieEM1MERTUF…
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case - ChartMill
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxQOFNTZy11MHpWc1NCaEQ0ZllCeDVMQWRnSXNKLUdCU0xSZFVnWVZpNU1BRnA3UVE2WHI5WFlJZWJaNXhvbG54ak9YZWs5cjRtM3I4MWVMRUMyVzBDUkV6QUx2SW16OG9hLVYzVTFVUnoxQmNZblgwOXZ4MlBkUk9JYjFyelhHXzVySkdOR3…
Catalyst Pharmaceuticals (CPRX) Could Be 60% Undervalued As Merger Approval Reshapes The Board - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQTFRTOThwcmlhaVRmbUE2a0FvYkdOMnQzZFhkUTZiYnIwM3NzWks1WWVDY1ZOVnEyUjY0WkpFd1BGVTF6NnJLOGFQckVFdzBfa1VhLXlYOXlYUGJZQ3V4WWNsYWhiYWdCemRQVEQ2X3FsNnI5ZXdxbThxdHJzZ04xM1JEREwtTzlnYjhWRU…
Wall Street Analysts Predict a 45.3% Upside in Catalyst (CPRX): Here's What You Should Know - qz.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPelVOeFdtbUQweHp2b3NjVHVfNmRBM3MzMjRRMmJwTlhzOGl2MHd1dUdGX0hiS2FaN3RKSHFFSTdhR2hUNnRyTTZvUHBHVjRCNUo4azZOVWNEa0EyX2xpaERmQnJEVUE1OEl1N0kwV1pzWjd6NDlvQ1RiYmk0MnhXaERxVGs3QVNlN25sRW…
CPRX — Frequently Asked Questions
What is the current share price of Catalyst Pharmaceuticals Inc (CPRX)?
As of 2026-09-07 16:24 PDT, Catalyst Pharmaceuticals Inc (CPRX) trades at $31.49 on NasdaqCM. Its 52-week range is $31.49 to $31.49.
What is the market capitalisation of CPRX?
Catalyst Pharmaceuticals Inc (CPRX) has a market capitalisation of $3.85B on NasdaqCM.
What is the P/E ratio of CPRX?
CPRX trades at a trailing price-to-earnings (P/E) ratio of 18.20. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.80.
What is the return on equity (ROE) of CPRX?
CPRX has a return on equity (ROE) of 24.50%. Its return on capital employed (ROCE) is 26.94%.
Is CPRX a good stock to buy?
This page provides a data-driven analysis of Catalyst Pharmaceuticals Inc (CPRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.